Get started
GENFITGENFITGENFIT

GENFIT

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

GNFT chart


Full chart

GNFT upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪168.88 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
9.840
Basic EPS (TTM)
0.450 EUR
Net income (FY)
‪−28.89 M‬ EUR
Revenue (FY)
‪28.57 M‬ EUR
Shares float
‪43.86 M‬
Beta (1Y)
1.67

Employees


Employees (FY)
159
Change (1Y)
+11 +7.43%
Revenue / Employee (1Y)
‪179.65 K‬ EUR
Net income / Employee (1Y)
‪−181.72 K‬ EUR

About GENFIT


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Pascal Prigent
Website
genfit.com
Headquarters
Loos
Founded
1999
ISIN
FR0004163111
FIGI
BBG000QH2N28
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GNFT news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

GNFT highest yielding bonds


GNFAA
GENFIT3,5%OCT25
Yield to maturity
0.40%
Maturity date
Oct 16, 2025

See all GNFT bonds 


Check out other big names from the same industry as GNFT.

Frequently Asked Questions


The current price of GNFT is 3.385 EUR — it has increased by 1.04% in the past 24 hours. Watch GENFIT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange GENFIT stocks are traded under the ticker GNFT.
GNFT stock has fallen by −0.44% compared to the previous week, the month change is a −5.31% fall, over the last year GENFIT has showed a 1.20% increase.
We've gathered analysts' opinions on GENFIT future price: according to them, GNFT price has a max estimate of 12.54 EUR and a min estimate of 7.00 EUR. Watch GNFT chart and read a more detailed GENFIT stock forecast: see what analysts think of GENFIT and suggest that you do with its stocks.
GNFT reached its all-time high on Feb 20, 2015 with the price of 68.530 EUR, and its all-time low was 1.135 EUR and was reached on Nov 21, 2011. View more price dynamics on GNFT chart.
See other stocks reaching their highest and lowest prices.
GNFT stock is 3.92% volatile and has beta coefficient of 1.67. Track GENFIT stock price on the chart and check out the list of the most volatile stocks — is GENFIT there?
Today GENFIT has the market capitalization of ‪168.79 M‬, it has decreased by −0.45% over the last week.
Yes, you can track GENFIT financials in yearly and quarterly reports right on TradingView.
GENFIT is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
GNFT earnings for the last half-year are 0.53 EUR per share, whereas the estimation was 0.31 EUR, resulting in a 70.97% surprise. The estimated earnings for the next half-year are 0.14 EUR per share. See more details about GENFIT earnings.
GENFIT revenue for the last half-year amounts to ‪61.20 M‬ EUR, despite the estimated figure of ‪47.50 M‬ EUR. In the next half-year revenue is expected to reach ‪37.55 M‬ EUR.
GNFT net income for the last half-year is ‪30.31 M‬ EUR, while the previous report showed ‪−8.04 M‬ EUR of net income which accounts for 477.00% change. Track more GENFIT financial stats to get the full picture.
No, GNFT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 31, 2025, the company has 159 employees. See our rating of the largest employees — is GENFIT on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENFIT EBITDA is ‪17.71 M‬ EUR, and current EBITDA margin is −122.29%. See more stats in GENFIT financial statements.
Like other stocks, GNFT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENFIT stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENFIT technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENFIT stock shows the sell signal. See more of GENFIT technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.